Strongbridge Biopharma PLC (SBBP) Rating Lowered to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) from a hold rating to a sell rating in a research note published on Wednesday.

According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “

SBBP has been the topic of several other research reports. ValuEngine lowered Strongbridge Biopharma PLC from a hold rating to a sell rating in a research note on Monday, October 2nd. Oppenheimer Holdings, Inc. initiated coverage on Strongbridge Biopharma PLC in a research note on Thursday, August 10th. They issued an outperform rating and a $12.00 price target on the stock. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. Strongbridge Biopharma PLC has an average rating of Hold and an average target price of $11.94.

Shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) remained flat at $6.15 during trading on Wednesday. The company’s stock had a trading volume of 69,307 shares. Strongbridge Biopharma PLC has a 52-week low of $2.00 and a 52-week high of $8.85. The firm’s market cap is $217.31 million. The stock has a 50 day moving average price of $6.79 and a 200 day moving average price of $5.70.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.84 million. On average, equities research analysts anticipate that Strongbridge Biopharma PLC will post ($2.48) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://ledgergazette.com/2017/10/08/strongbridge-biopharma-plc-sbbp-rating-lowered-to-sell-at-zacks-investment-research.html.

A number of hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at $277,000. State Street Corp acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at $443,000. Nexthera Capital LP acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at $477,000. Vanguard Group Inc. acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at $474,000. Finally, Northern Trust Corp acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at $1,462,000. 63.65% of the stock is currently owned by institutional investors and hedge funds.

About Strongbridge Biopharma PLC

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

google_ad_client = AdClientID; google_ad_slot = "4341240663"; google_ad_width = 728; google_ad_height = 90; google_ad_channel="6345773562,1028988335,8569953935"

According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “

SBBP has been the topic of several other research reports. ValuEngine lowered Strongbridge Biopharma PLC from a hold rating to a sell rating in a research note on Monday, October 2nd. Oppenheimer Holdings, Inc. initiated coverage on Strongbridge Biopharma PLC in a research note on Thursday, August 10th. They issued an outperform rating and a $12.00 price target on the stock. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. Strongbridge Biopharma PLC has an average rating of Hold and an average target price of $11.94.

Shares of Strongbridge Biopharma PLC (NASDAQ:SBBP) remained flat at $6.15 during trading on Wednesday. The company’s stock had a trading volume of 69,307 shares. Strongbridge Biopharma PLC has a 52-week low of $2.00 and a 52-week high of $8.85. The firm’s market cap is $217.31 million. The stock has a 50 day moving average price of $6.79 and a 200 day moving average price of $5.70.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $0.84 million. On average, equities research analysts anticipate that Strongbridge Biopharma PLC will post ($2.48) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://ledgergazette.com/2017/10/08/strongbridge-biopharma-plc-sbbp-rating-lowered-to-sell-at-zacks-investment-research.html.

A number of hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at $277,000. State Street Corp acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at $443,000. Nexthera Capital LP acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at $477,000. Vanguard Group Inc. acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at $474,000. Finally, Northern Trust Corp acquired a new stake in Strongbridge Biopharma PLC in the 2nd quarter valued at $1,462,000. 63.65% of the stock is currently owned by institutional investors and hedge funds.

About Strongbridge Biopharma PLC

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Get a free copy of the Zacks research report on Strongbridge Biopharma PLC (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.